<?xml version="1.0" encoding="UTF-8"?>
<collection>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd http://dublincore.org/schemas/xmls/qdc/dcterms.xsd"><dc:language>eng</dc:language><dc:creator>Pradhan, Ranjit</dc:creator><dc:creator>Sakib, M Sadman</dc:creator><dc:creator>Fischer, Andre</dc:creator><dc:creator>Kaurani, Lalit</dc:creator><dc:creator>Krüger, Dennis M</dc:creator><dc:creator>Pena, Tonatiuh</dc:creator><dc:creator>Burkhardt, Susanne</dc:creator><dc:creator>Schütz, Anna-Lena</dc:creator><dc:creator>Kronenberg-Versteeg, Deborah</dc:creator><dc:creator>Delalle, Ivana</dc:creator><dc:creator>Sananbenesi, Farahnaz</dc:creator><dc:title>lncRNA Glelr modulates microglia inflammatory programs in association with PU.1.</dc:title><dc:subject>info:eu-repo/classification/ddc/570</dc:subject><dc:subject>RNA, Long Noncoding: metabolism</dc:subject><dc:subject>RNA, Long Noncoding: genetics</dc:subject><dc:subject>Microglia: metabolism</dc:subject><dc:subject>Animals</dc:subject><dc:subject>Humans</dc:subject><dc:subject>Mice</dc:subject><dc:subject>Trans-Activators: metabolism</dc:subject><dc:subject>Trans-Activators: genetics</dc:subject><dc:subject>Proto-Oncogene Proteins: metabolism</dc:subject><dc:subject>Proto-Oncogene Proteins: genetics</dc:subject><dc:subject>Inflammation: metabolism</dc:subject><dc:subject>Inflammation: genetics</dc:subject><dc:subject>Mice, Inbred C57BL</dc:subject><dc:subject>Cells, Cultured</dc:subject><dc:subject>Aging: metabolism</dc:subject><dc:subject>Astrocytes: metabolism</dc:subject><dc:subject>3222401L13Rik/ENSG00000272070</dc:subject><dc:subject>Alzheimer's disease</dc:subject><dc:subject>Long non-coding RNA (lncRNA)</dc:subject><dc:subject>Microglia</dc:subject><dc:subject>Neuroinflammation</dc:subject><dc:subject>Non-coding RNAome</dc:subject><dc:subject>PU.1 (SPI1)</dc:subject><dc:subject>RNA, Long Noncoding</dc:subject><dc:subject>Trans-Activators</dc:subject><dc:subject>Proto-Oncogene Proteins</dc:subject><dc:description>Long non-coding RNAs (lncRNAs) are emerging as key regulators of brain function, but their contribution to microglial aging and neurodegenerative disease remains largely unknown. Because only 1.5% of the human genome encodes proteins, whereas the vast majority of transcripts belong to the largely unexplored non-coding RNAome, elucidating the functions of non-coding RNAs provides an unprecedented opportunity to expand the space for therapeutic discovery. We recently identified the glia-enriched lncRNA Glelr as upregulated in the aging mouse hippocampus. Here, we investigated its function in microglia and its human homolog GLELR. We found that Glelr/GLELR is expressed in both astrocytes and microglia and increases with age. Knockdown of Glelr in primary microglia led to enhanced expression of pro-inflammatory cytokines, including TNFα, and increased phagocytic activity. RNA-sequencing revealed widespread transcriptional changes enriched for TNF and complement signaling pathways. The human homolog GLELR showed conserved functions in iPSC-derived microglia, where its loss similarly promoted inflammatory gene expression and phagocytosis. Mechanistically, Glelr interacts with the microglial transcription factor PU.1, and its depletion overlapped with PU.1-driven transcriptional programs. Consistent with these findings, GLELR expression was significantly reduced in postmortem Alzheimer's disease (AD) brains, and AD-associated genes were enriched among Glelr-regulated targets. Together, our results identify Glelr/GLELR as a conserved, aging-associated lncRNA that modulates microglial inflammatory states through interaction with PU.1. This work links glial lncRNA regulation to AD-related neuroinflammation and suggests GLELR as a potential molecular target to fine-tune microglial activity in neurodegenerative diseases.</dc:description><dc:source>Neurobiology of disease 222, 107366 (2026). doi:10.1016/j.nbd.2026.107366</dc:source><dc:type>info:eu-repo/semantics/article</dc:type><dc:type>info:eu-repo/semantics/publishedVersion</dc:type><dc:publisher>Elsevier</dc:publisher><dc:date>2026</dc:date><dc:rights>info:eu-repo/semantics/closedAccess</dc:rights><dc:coverage>DE</dc:coverage><dc:identifier>https://pub.dzne.de/record/286089</dc:identifier><dc:identifier>https://pub.dzne.de/search?p=id:%22DZNE-2026-00385%22</dc:identifier><dc:audience>Researchers</dc:audience><dc:relation>info:eu-repo/semantics/altIdentifier/pmid/pmid:41895620</dc:relation><dc:relation>info:eu-repo/semantics/altIdentifier/issn/1095-953X</dc:relation><dc:relation>info:eu-repo/semantics/altIdentifier/issn/0969-9961</dc:relation><dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.nbd.2026.107366</dc:relation></oai_dc:dc>

</collection>